Drug evaluation: ISIS-301012, an antisense oligonucleotide for the treatment of hypercholesterolemia

被引：0
|
作者：
Burnett, John R. [1 ]
机构：
[1] Royal Perth Hosp, Dept Core Clin Pathol & Biochem, PathW Lab Med WA, Perth, WA 6847, Australia
来源：
CURRENT OPINION IN MOLECULAR THERAPEUTICS | 2006年 / 8卷 / 05期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
ISIS-301012 is an antisense oligonucleotide inhibitor of apolipoprotein B-100, which is being developed by Isis Pharmaceuticals Inc for the potential treatment of hypercholesterolemia. A subcutaneous injectable formulation is currently undergoing phase II clinical trials, while phase I trials are underway with an oral formulation of the drug.
引用
收藏
页码：461 / 467
页数：7
相关论文
共 50 条
  • [31] Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302)
    Watanabe, Tanya A.
    Geary, Richard S.
    Levin, Arthur A.
    OLIGONUCLEOTIDES, 2006, 16 (02) : 169 - 180
  • [32] ISIS 301012, an antisense inhibitor of APOB, produces significant additional reduction of LDL-C & APOB in hypercholesterolemic subjects on statins not meeting target
    Kastelein, J. P.
    Akdim, F.
    Trip, M. D.
    Sijbrands, E.
    Jukema, F.
    Visseren, F. J.
    Bradley, J. D.
    Wedel, M. K.
    Su, J.
    Chuang, E.
    Tribble, D.
    Stein, E.
    ATHEROSCLEROSIS SUPPLEMENTS, 2007, 8 (01) : 198 - 199
  • [33] ANTISENSE OLIGONUCLEOTIDE TREATMENT OF PROSTATE-CANCER
    RUBENSTEIN, M
    MUCHNIK, S
    DUNEA, G
    GUINAN, P
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1993, : 198 - 198
  • [34] Antisense oligonucleotide development for the treatment of muscular dystrophies
    Bao, Tri Le
    Veedu, Rakesh N.
    Fletcher, Sue
    Wilton, Steve D.
    EXPERT OPINION ON ORPHAN DRUGS, 2016, 4 (02): : 139 - 152
  • [35] The Role of Antisense Oligonucleotide Therapy in Patients with Familial Hypercholesterolemia: Risks, Benefits, and Management Recommendations
    Agarwala, Anandita
    Jones, Peter
    Nambi, Vijay
    CURRENT ATHEROSCLEROSIS REPORTS, 2015, 17 (01) : 1 - 8
  • [36] Treatment of chronic hepatitis C with ISIS 14803, an antisense oligonucleotide inhibitor of HCV effect of target region sequence on antiviral efficacy.
    Soler, M
    McHutchison, JG
    Kwoh, J
    Dort, A
    Pawlotsky, JM
    HEPATOLOGY, 2002, 36 (04) : 280A - 280A
  • [37] Inhibition of CMV replication in human RPE cells following treatment with fomivirsen-sodium (isis 2922) a CMV antisense oligonucleotide.
    Detrick, B
    Hooks, JJ
    Nagineni, C
    Henry, S
    Anderson, K
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1997, 38 (04) : 5162 - 5162
  • [38] Efficacy and safety of ISIS 2302 (ICAM-I antisense oligonucleotide) treatment of steroid-dependent Crohn's disease.
    Yacyshyn, B
    Woloschuk, B
    Yacyshyn, MB
    Martini, D
    Doan, K
    Tami, J
    Bennett, F
    Kisner, D
    Shanahan, W
    GASTROENTEROLOGY, 1997, 112 (04) : A1123 - A1123
  • [39] Making sense of antisense: ISIS 2302 (alicaforsen) in the treatment of pouchitis
    Fefferman, DS
    Farrell, RJ
    INFLAMMATORY BOWEL DISEASES, 2004, 10 (04) : 487 - 488
  • [40] A sense oligonucleotide specifically reverses the prothrombin depletion and anticoagulation caused by ISIS 401025, an antisense oligonucleotide targeting prothrombin RNA in mice.
    Zhao, Chenguang
    Monia, Breit P.
    Siwkowski, Andy
    Freier, Sue
    Witchell, Donna
    Zhang, Hong
    BLOOD, 2007, 110 (11) : 281A - 281A
12345